Interested in future Long COVID studies at UF/UF Health? Visit Registry for People with Long COVID for more information.
Addition of Pembrolizumab to Usual Intravesical Gemcitabine for Treatment of BCG-Unresponsive NMIBC
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
TREAT-MS
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early…
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 60 Years
- Sexes
- All
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 12 Years - 99 Years
- Sexes
- All